CIC bioGUNE receives the Spanish Association Against Cancer Scientific Foundation Centres Accreditation

CIC bioGUNE has been accredited by the Scientific Foundation of the Spanish Association Against Cancer as one of the leading cancer research centres in Spain, standing out for its commitment to scientific excellence and precision medicine.

Its PreMetaCan project, focused on cancer metabolism, and its multidisciplinary approach strengthen its impact on the diagnosis and treatment of the disease.

Internationally recognised, CIC bioGUNE continues to consolidate its position as a leader in biomedical research and the fight against cancer.

CIC bioGUNE, a member of BRTA, has been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC) as one of the 13 most outstanding cancer research centres in Spain. This prestigious recognition underlines the centre’s commitment to research excellence in oncology and reinforces its position as an international benchmark in the fight against cancer.

The Science Foundation has been instrumental in supporting research centres of excellence in the field of oncology since 2018. With the creation of the Foundation Centres Accreditation in 2024, the Foundation has taken a decisive step in the promotion of cancer research. This new accreditation system not only values scientific excellence, but also the quality of the institutional management of the centres, which play a crucial role in the advancement of scientific projects in the fight against cancer. In total, 13 centres have received this distinction, consolidating their position as national and international benchmarks in the field of cancer research.

This recognition reinforces CIC bioGUNE’s capacity to generate impact on both science and society. Accreditation opens up access to exclusive funding calls and strengthens the visibility and impact of research projects. Through this initiative, the Science Foundation reaffirms its commitment to excellence and innovation in cancer research, working towards the ambitious goal of achieving a 70% overall cancer survival rate by 2030.

CIC bioGUNE and its commitment to cutting-edge oncology research

CIC bioGUNE has maintained a strong commitment to oncology research, backed by its multidisciplinary approach in areas such as ‘Metabolism and Cell Signalling in Diseases’ and ‘Molecular Recognition and Host-Pathogen Interactions’. One of the flagship projects in this field is PreMetaCan, a pioneering research project that has recently received 2 million euros from the Spanish Association Against Cancer (AECC). This project, led by Arkaitz Carracedo and directed by Jesús Jiménez-Barbero, focuses on studying how metabolism influences the development and resistance to cancer, with the aim of optimising combined therapies and improving the effectiveness of personalised treatments. The research employs advanced technologies, such as magnetic resonance imaging (MRI), and explores innovative areas such as metabolomics, glycomics and translational oncology.

The accreditation received not only underlines the importance of projects such as PreMetaCan, but also CIC bioGUNE’s continued commitment to precision medicine, which relies on a combination of basic and applied research to improve both the diagnosis and treatment of various forms of cancer. CIC bioGUNE’s advanced infrastructure, which includes technological platforms in genomics, proteomics and metabolomics, is essential to enable scientific research that generates a tangible impact on health and society.

A multidisciplinary and translational research model at the service of society

CIC bioGUNE stands out for its ability to approach research from a multidisciplinary approach, integrating areas such as chemistry, biology, biomedicine and mathematics, with the aim of developing new tools and approaches to cancer treatment. The centre is actively working on generating fundamental knowledge and exploring new technologies, which, in the long term, could lead to clinical, diagnostic and therapeutic applications. With an annual average of more than five patents registered, CIC bioGUNE demonstrates its capacity for innovation, collaborating with national and international institutions to advance innovative solutions in the fight against cancer.

In addition, CIC bioGUNE maintains a strong commitment to the training of new research talent, working closely with universities and other research centres to promote scientific and technological innovation. Through its multidisciplinary approach, CIC bioGUNE continues to consolidate its position as a key player in biomedical research, with growing recognition at national and international level, especially in the field of oncology.

An international benchmark in biomedical research

CIC bioGUNE’s impact on oncology research is widely recognised both nationally and internationally. The centre has received numerous prestigious awards, including nine European Research Council (ERC) grants and the Severo Ochoa Seal of Excellence from the Spanish Ministry of Science, Innovation and Universities. The recent accreditation by the AECC Scientific Foundation further reinforces its leadership in biomedical research, highlighting its contribution to the fight against cancer and its alignment with the AECC’s goals to improve overall cancer survival.